Search
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalIn the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Synonyms: t-PA, t-plasminogen activatorTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration
Synonyms: HuMax-TF-ADCLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalIt was approved by the U.S. … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-2 Receptor AntagonistsCystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Benzonatate
go.drugbank.com/drugs/DB00868Approved[A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex. … Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.
Categories: Decreased Tracheobronchial Stretch Receptor ActivityLenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]
Dosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin inhibits the reuptake of biogenic amines, increasing available neurotransmitter levels at the synaptic cleft. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.
Synonyms: (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine, 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepinCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsLycopene
go.drugbank.com/drugs/DB11231Approved, A27243] that gives the red hue. … Lycopene may undergo extensive isomerization that allows 1056 theoretical cis-trans configurations; however, the all-trans configuration of lycopene is the most predominant isomer found in foods [A27242
Mixtures: RE FAC-xLecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Ivabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the … Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate